The Perrigo Company,  a leading global healthcare supplier that develops, manufactures and distributes OTC and prescription pharmaceuticals, nutritional products, API and consumer products,  has started shipping over-the-counter nicotine polacrilex mini lozenge USP, two mg (mint flavour) and four mg (mint flavour).

This launch represents the first to market nicotine mini lozenge products for the store brand market. The mint flavoured mini lozenges are marketed under retailer and wholesalers' store, or own brand labels and are comparable to GlaxoSmithKline's Nicorette Mini Lozenge. The product is indicated to reduce withdrawal symptoms, including nicotine craving, associated with quitting smoking.

"This launch strengthens Perrigo's leading store brand position in smoking cessation products, which also includes coated and uncoated flavoured gums and regular size lozenges," said Joseph C Papa, Perrigo's chairman, president and CEO. Nicorette Mini Lozenge is selling at an annual rate estimated at over $30 million at all retail outlets.